Impact of systemic autoimmune diseases in maternal, fetal and neonatal outcomes in Spain.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42421209.
- Also identified by DOI 10.1093/rheumatology/keag358.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pregnancy in autoimmune disease is increasingly feasible but carries heterogeneous maternal and perinatal risks beyond hypertensive disorders. We aimed to quantify disease-specific risks of maternal, fetal and neonatal outcomes across autoimmune diseases in a nationwide cohort, explicitly distinguishing primary vs secondary APS. We analyzed pregnancy-related hospitalizations in Spain (SNHDD, 2016-2022). Exposures were systemic lupus erythematosus (SLE), primary Sjögren syndrome (SjS), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), sarcoidosis, Behçet disease, and antiphospholipid syndrome (APS) (primary/secondary). Outcomes included preeclampsia (PE), preeclampsia with severe features (PESC), composite maternal morbidity (cesarean delivery, postpartum hemorrhage, thrombosis, stroke, ICU admission), and composite fetal/neonatal morbidity-mortality (fetal distress, fetal growth restriction, preterm delivery, abruptio placentae, stillbirth, neonatal death). In 1,973 249 Spanish pregnancy hospitalizations, 5,727 involved autoimmune disease. Risks clustered by disease: SLE (PE OR 1.78; PESC 2.17; composite maternal 1.35; fetal/neonatal 1.16), primary APS (PE 1.50; PESC 1.88; maternal 1.66; fetal/neonatal 1.10), secondary APS (PE 2.61; PESC 3.47; maternal 1.94), and MCTD (PE 4.57; PESC 7.24) showed the strongest signals. SSc increased composite maternal (1.62) and fetal/neonatal (1.69) risk; SjS raised cesarean and selected fetal outcomes; Behçet disease mainly increased maternal thrombosis (9.31); and sarcoidosis showed no independent associations. Pregnancies affected by autoimmune disease exhibit distinct, disease-specific patterns of hypertensive, maternal, and fetal/neonatal risk, with the most consistently elevated risks observed in SLE, APS (especially secondary), and MCTD. These comparative estimates may support risk-stratified, guideline-concordant care and inform counseling, surveillance, and delivery planning, with explicit consideration of comorbidity burden.